GLP1R and type 2 diabetes mellitus: The activated G protein then goes on to facilitate downstreamsignaling pathways.13,14 The GLP-1 and GCG endogenouspeptides play a central role in regulating blood glucose levels, butmarketed peptide APIs such as Semaglutide, Exenatide, and Liraglutideare only efficacious as a single agonist (monoagonist) of the GLP-1Rfor treatment of T2DM.15 Moreover, Liraglutideis prone to peptide aggregation at its injection site16,17 leading to undesired side effects.